English

Interim report Q1, 2024: Strong growth in APAC and solid margins

Report this content

First quarter

  • Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.
  • Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas.
  • Sales per business area, in local currencies was +12% in Consumables, +8% in Technologies and -12% in Genetics.
  • Gross margin increased to 57.1% (56.8).
  • Operating income before depreciation and amortisation (EBITDA) increased to SEK 272 (262) million, giving an EBITDA margin of 32.4% (30.6).
  • Operating cash flow increased to SEK 198 million (160).
  • Net income was SEK 115 (99) million, resulting in earnings per share of SEK 0.85 (0.74).
  • The product area Genomics was previously reported in Consumables business area but is now part of Genetic Services business area, renamed to Genetics business area.

     

Gothenburg, April 18, 2024
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 18-04-2024 08:00 CET.

Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_____________________________________________________________________________________________________________________________________________________________

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient’s fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden. 

Vitrolife Group’s products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to enable people to fulfil the dream of having a healthy baby. The Vitrolife AB (publ) share is listed on the Nasdaq Stockholm.
_____________________________________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.

Subscribe

Documents & Links